Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Jul 10, 2012

23andMe Snaps Up CureTogether

  • 23andMe today said it acquired CureTogether, the membership-based health information website. The price and other terms were not disclosed.

    In a statement, 23andMe said CureTogether will bring it additional tools and systems for gathering data from health-based communities complementary to the personal genetics company’s existing platforms, allowing customers to share quantitative information on more than 500 medical conditions, talk about sensitive symptoms and compare which treatments work best for them as they track their health.

    23andMe said the acquisition—the company’s first since it was founded in 2006—would improve its ability to gather data for research, while enriching its online community with interactions from CureTogether users.

    CureTogether was launched in 2008 with the initial purpose of assisting people who live in chronic pain, and expanded from its initial three conditions as members joined and requested that their conditions be added to the site’s ongoing study. Cure Together has grown its platform to more than four million phenotypic data points across different health conditions designed to help inform future genetic discoveries.

    "There are tremendous opportunities for our members and for future research by integrating the 23andMe and the CureTogether platforms and phenotypic data," CureTogether cofounder Daniel Reda said in the statement. Reda and cofounder Alexandra Carmichael will join 23andMe as senior product managers.

Related content


GEN Jobs powered by HireLifeScience.com connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
More »

Be sure to take the GEN Poll

What Does Brexit Mean for Biotech?

Do you agree with the contention that Brexit will NOT have a long-term negative impact on the British biotech industry?

More »